MIRM
Income statement / Annual
Last year (2024), Mirum Pharmaceuticals, Inc.'s total revenue was $336.89 M,
an increase of 80.76% from the previous year.
In 2024, Mirum Pharmaceuticals, Inc.'s net income was -$87.94 M.
See Mirum Pharmaceuticals, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
| Operating Revenue |
$336.89 M |
$186.37 M |
$77.06 M |
$19.14 M |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$81.64 M
|
$47.04 M
|
$12.37 M
|
$1.90 M
|
$623,000.00
|
$324,000.00
|
$0.00
|
| Gross Profit |
$255.25 M
|
$139.34 M
|
$64.69 M
|
$17.24 M
|
-$623,000.00
|
-$324,000.00
|
$0.00
|
| Gross Profit Ratio |
0.76
|
0.75
|
0.84
|
0.9
|
0
|
0
|
0
|
| Research and Development Expenses |
$140.63 M
|
$102.61 M
|
$106.84 M
|
$131.43 M
|
$81.61 M
|
$42.99 M
|
$2.33 M
|
| General & Administrative Expenses |
$0.00
|
$139.58 M
|
$16.96 M
|
$59.22 M
|
$22.69 M
|
$11.75 M
|
$877,500.00
|
| Selling & Marketing Expenses |
$0.00
|
$6.30 M
|
$72.11 M
|
$9.20 M
|
$0.00
|
$0.00
|
-$292,500.00
|
| Selling, General & Administrative Expenses |
$202.22 M
|
$145.88 M
|
$89.07 M
|
$59.22 M
|
$22.69 M
|
$11.75 M
|
$585,000.00
|
| Other Expenses |
$0.00
|
$0.00
|
$365,000.00
|
$107.42 M
|
-$192,000.00
|
-$21,000.00
|
$0.00
|
| Operating Expenses |
$342.85 M
|
$248.49 M
|
$195.91 M
|
$190.65 M
|
$104.30 M
|
$54.74 M
|
$2.92 M
|
| Cost And Expenses |
$424.49 M
|
$295.53 M
|
$208.28 M
|
$192.55 M
|
$104.30 M
|
$54.74 M
|
$2.92 M
|
| Interest Income |
$13.79 M
|
$13.74 M
|
$3.86 M
|
$366,000.00
|
$1.56 M
|
$2.23 M
|
$87,000.00
|
| Interest Expense |
$14.31 M
|
$15.11 M
|
$15.98 M
|
$17.59 M
|
$335,000.00
|
$0.00
|
$0.00
|
| Depreciation & Amortization |
$23.63 M
|
$10.83 M
|
$3.68 M
|
$975,000.00
|
$623,000.00
|
$324,000.00
|
$4.37 M
|
| EBITDA |
-$48.97 M |
-$136.49 M |
-$122.41 M |
-$65.39 M |
-$102.31 M |
-$52.21 M |
-$17.33 M |
| EBITDA Ratio |
-0.15
|
-0.73
|
-1.59
|
-3.42
|
0
|
0
|
0
|
| Operating Income Ratio |
-0.26
|
-0.59
|
-1.7
|
-9.06
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$694,000.00
|
-$53.27 M
|
-$10.85 M
|
$89.46 M
|
$1.03 M
|
$2.21 M
|
-$14.43 M
|
| Income Before Tax |
-$86.91 M
|
-$162.42 M
|
-$142.07 M
|
-$83.95 M
|
-$103.26 M
|
-$52.53 M
|
-$17.35 M
|
| Income Before Tax Ratio |
-0.26
|
-0.87
|
-1.84
|
-4.39
|
0
|
0
|
0
|
| Income Tax Expense |
$1.03 M
|
$991,000.00
|
-$6.41 M
|
$37,000.00
|
$6,000.00
|
$21,000.00
|
-$4.37 M
|
| Net Income |
-$87.94 M
|
-$163.42 M
|
-$135.67 M
|
-$83.99 M
|
-$103.27 M
|
-$52.55 M
|
-$17.35 M
|
| Net Income Ratio |
-0.26
|
-0.88
|
-1.76
|
-4.39
|
0
|
0
|
0
|
| EPS |
-1.85 |
-4 |
-4.01 |
-2.77 |
-4.09 |
-2.29 |
-0.75 |
| EPS Diluted |
-1.85 |
-4 |
-4.01 |
-2.77 |
-4.09 |
-2.29 |
-0.75 |
| Weighted Average Shares Out |
$47.52 M
|
$40.89 M
|
$33.84 M
|
$30.32 M
|
$25.25 M
|
$22.99 M
|
$22.99 M
|
| Weighted Average Shares Out Diluted |
$47.52 M
|
$40.89 M
|
$33.84 M
|
$30.32 M
|
$25.25 M
|
$22.99 M
|
$22.99 M
|
| Link |
|
|
|
|
|
|
|
